| Identification | Back Directory | [Name]
4-bromo-N'-butylbenzohydrazide | [CAS]
537672-41-6 | [Synonyms]
UF 010
CS-2427
UF010, >98%
UF-010; UF 010
UF010 >=98% (HPLC)
4-bromo-N'-butylbenzohydrazide
4-Bromobenzoic acid 2-butylhydrazide
Benzoic acid, 4-bromo-, 2-butylhydrazide | [Molecular Formula]
C11H15BrN2O | [MDL Number]
MFCD03603083 | [MOL File]
537672-41-6.mol | [Molecular Weight]
271.15 |
| Chemical Properties | Back Directory | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
insoluble in H2O; ≥10.65 mg/mL in DMSO; ≥20.85 mg/mL in EtOH | [form ]
solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
UF010 is a class I HDAC inhibitor with IC50 values of 0.06, 0.1, 0.5, and 1.5 μM for HDAC3, 2, 1, and 8, respectively. It is more than 6-fold selective for these class I HDACs over any additional HDACs. UF010 is reported to inhibit cancer cell proliferation with a mean GI50 value of 2.94 μM when screened against the NCI-60 panel of cancer cell lines and functions by blocking the G1/S phase of the cell cycle. | [Uses]
4-Bromo-2-butylhydrazide Benzoic Acid inhibits histone deacetylases (HDAC) as potential clinical anticancer therapies. | [in vivo]
UF010 (15 mg/kg, Intraperitoneal injection, single dose) contributes considerably to the inflammatory regulation of hippocampal neurons in postoperative cognitive dysfunction (POCD) mice[4].
UF010 (15 mg/kg, Intraperitoneal injection, single dose) has antitumor therapeutic efficacy in the 4T1-Luc tumor-bearing mouse model[5]. | Animal Model: | postoperative cognitive dysfunction (POCD) mice[4] | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Weakened the infiltration of CD4+ T cells and NK cells in hippocampal tissues.
Reduced inflammatory parameters in serum and hippocampal tissues, such as interleukin 6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-α) levels.
Activated the NF-κB/p65, JAK/STAT and TLR/MyD88 pathways. |
| Animal Model: | 4T1-Luc tumor-bearing mouse model[5] | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Inhibited the tumor growth rate percentage to 55.56, 38.36, 39.52% at days 7, 14, and 21.
Induced high levels of ROS generation, causing apoptosis-mediated tumor cell death. |
| [IC 50]
HDAC1: 1.42 μM (); HDAC2: 0.32 μM (IC50); HDAC3: 256.7 nM (IC50); HDAC6: 18.93 μM (IC50); HDAC8: 3.97 μM (IC50); IL-6 | [References]
[1]. wang y, stowe rl, pinello ce, et al. identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class i histone deacetylases. chem biol, 2015, 22(2): 273-284. |
|
| Company Name: |
D&C Chemicals
|
| Tel: |
+86-21-58447131 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList16963/0_EN.htm |
|